Browsing: weightloss

Medicare’s New GLP-1 Bridge: Weight-Loss Help for $50 a Month – Daily Independent Skip to main content Log in SPONSORED CONTENT

Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it to compete with rival Novo Nordisk’sWegovy pill in the U.K

Social media has labelled GLP-1 receptor agonists as “miracle” weight-loss drugs. However, these medicines represent more than a passing trend. Obesity is a complex chronic disease often associated with diabetes, hypertension and cardiovascular problems. GLP-1 receptor agonists, initially developed for type 2 diabetes, now play an important role in obesity management

On August 10, the British regulator approved Eli Lilly’s Foundayo pill for weight management and the treatment of type 2 diabetes. Initially, the drug will be available on the private market, with an NHS decision expected by November 18

The recent increasing adoption of GLP-1 drugs has fundamentally changed the landscape of weight loss and health habits. Prescription medicines such as Ozempic, Wegovy, and Mounjaro

New research suggests weight-loss drugs, such as semaglutide and tirzepatide, are being used by some high-level athletes without a medical need, raising questions about their effect on performance and athlete health

A new study has found that weight-loss drugs may be reshaping people’s food shopping habits

When Lisa Rees took her first dose of weight-loss medication in April, she hoped she would end up losing a few kilograms

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first…

The past few years have been rough on Pfizer (NYSE: PFE). The company has generally posted subpar financial results due to weakness within its coronavirus franchise, which once helped it become the first biopharmaceutical company to achieve $100 billion in annual sales. The drugmaker is looking to turn things around by developing potential blockbuster products,…